The new prophylactic strategy for colitic cancer in inflammatory bowel disease by modulating microbiota

References

• Mayer L. Evolving paradigms in the pathogenesis of IBD. J gastroenterol 2010;45:9–16.
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35.
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813–16.
   PubMed Web of Science ®Google Scholar
• Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis (Basel, Switzerland) 2010;28:619–24.
   PubMed Web of Science ®Google Scholar
• Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807–16.
   PubMed Web of Science ®Google Scholar
• Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7–17.
   PubMed Web of Science ®Google Scholar
• Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis (Basel, Switzerland) 2003;21:105–28.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis 2006;19:475–84.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–29.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008;43:1–17.
   PubMed Web of Science ®Google Scholar
• Sansonetti PJ, Di Santo JP. Debugging how bacteria manipulate the immune response. Immunity 2007;26:149–61.
   PubMed Web of Science ®Google Scholar
• Asquith M, Powrie F. An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med 2010;207:1573–7.
   PubMed Web of Science ®Google Scholar
• Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869–81.
   PubMed Web of Science ®Google Scholar
• Fukata M, Hernandez Y, Conduah D, Cohen J, Chen A, Breglio K, Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 2009;15:997–1006.
   PubMed Web of Science ®Google Scholar
• Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009;136:65–80.
   PubMed Web of Science ®Google Scholar
• Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol 2005;21:414–18.
   PubMed Web of Science ®Google Scholar
• Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011;46:479–86.
   PubMed Web of Science ®Google Scholar
• Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745–57.
   Google Scholar
• Cunliffe RN, Kamal M, Rose FR, James PD, Mahida YR. Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J Clin Pathol 2002;55:298–304.
   PubMed Web of Science ®Google Scholar
• Deguchi Y, Andoh A, Inatomi O, Araki Y, Hata K, Tsujikawa T, Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med 2005;16:605–8.
   PubMed Web of Science ®Google Scholar
• Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000;95:S19–21.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr Opin Gastroenterol 2001;17:331–5.
   PubMed Web of Science ®Google Scholar
• Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4:e6026.
   PubMed Web of Science ®Google Scholar
• Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011;6:e16393.
   PubMed Web of Science ®Google Scholar
• Boulard O, Kirchberger S, Royston DJ, Maloy KJ, Powrie FM. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J Exp Med 2012;209:1309–24.
   Google Scholar
• Gunther U, Kusch D, Heller F, Burgel N, Leonhardt S, Daum S, Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis 2011;26:667–72.
   PubMed Web of Science ®Google Scholar
• Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003;24:443–51.
   PubMed Web of Science ®Google Scholar
• Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011;106:1340–50.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Griffiths TA, Surette MG, Ness S, Rioux KP. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression. Inflamm Bowel Dis 2009;15:985–96.
   Google Scholar
• Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:841–55.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 106:731–6.
   Google Scholar
• Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929–33.
   PubMed Web of Science ®Google Scholar
• Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889–93.
   PubMed Web of Science ®Google Scholar
• Kohno H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res 2007;13:2519–25.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638–45.
   PubMed Web of Science ®Google Scholar
• Karagiannides I, Kokkotou E, Tansky M, Tchkonia T, Giorgadze N, O'Brien M, Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci USA 2006;103:5207–12.
   Google Scholar
• Okamoto K, Fukatsu K, Ueno C, Shinto E, Hashiguchi Y, Nagayoshi H, T lymphocyte numbers in human gut associated lymphoid tissue are reduced without enteral nutrition. Jpen 2005;29:56–8.
   Google Scholar
• Desreumaux P. Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 2006:24:2–9.
   PubMed Web of Science ®Google Scholar
• Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116:602–9.
   PubMed Web of Science ®Google Scholar
• Ramakers JD, Mensink RP, Schaart G, Plat J. Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids 2007;42:687–98.
   PubMed Web of Science ®Google Scholar
• Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol 2009;15:2570–8.
   PubMed Web of Science ®Google Scholar
• Rajendran N, Kumar D. Role of diet in the management of inflammatory bowel disease. World J Gastroenterol 2010;16:1442–8.
   PubMed Web of Science ®Google Scholar
• Mishkin S. Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Am J Clin Nutr 1997;65:564–7.
   PubMed Web of Science ®Google Scholar
• Mandir N, Englyst H, Goodlad RA. Resistant carbohydrates stimulate cell proliferation and crypt fission in wild-type mice and in the Apc(Min/+) mouse model of intestinal cancer, association with enhanced polyp development. Br J Nutr 2008;100:711–21.
   Google Scholar
• Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008;57:1509–17.
   PubMed Web of Science ®Google Scholar
• Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009;15:2087–94.
   PubMed Web of Science ®Google Scholar
• Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci USA 2011;108:6615–20.
   PubMed Web of Science ®Google Scholar
• Villegas I, Sanchez-Fidalgo S, de la Lastra C A. Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice. Mol Nutr Food Res 2011;55:259–67.
   Web of Science ®Google Scholar
• Ostrowski J, Janik P, Nowacki M, Janczewska I, Przybyszewska M, Szaniawska B, Serum retinol level in patients with colorectal premalignant and malignant lesions. Br J Cancer 1987;55:203–5.
   Google Scholar
• Yasui Y, Hosokawa M, Mikami N, Miyashita K, Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem Biol Interact 2011;193:79–87.
   Google Scholar
• Yang CS, Lu G, Ju J, Li GX. Inhibition of inflammation and carcinogenesis in the lung and colon by tocopherols. Ann N Y Acad Sci 2010;1203:29–34.
   PubMed Web of Science ®Google Scholar
• Raman M, Milestone AN, Walters JR, Hart AL, Ghosh S. Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therap Adv Gastroenterol 2011;4:49–62.
   PubMedGoogle Scholar
• Monk JM, Kim W, Callaway E, Turk HF, Foreman JE, Peters JM, Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARdelta in inflammation-induced colon carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2011;302:G153–67.
   Google Scholar
• Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, Glickman JN, Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 2007;28:1991–5.
   PubMed Web of Science ®Google Scholar
• Pot GK, Majsak-Newman G, Geelen A, Harvey LJ, Nagengast FM, Witteman BJ, Fish consumption and markers of colorectal cancer risk: a multicenter randomized controlled trial. Am J Clin Nutr 2009;90:354–61.
   PubMed Web of Science ®Google Scholar
• Evans NP, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr 2010;140:515–21.
   Web of Science ®Google Scholar
• Li H, Wu WK, Li ZJ, Chan KM, Wong CC, Ye CG, 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br J Pharmacol 2010;160:1352–61.
   PubMed Web of Science ®Google Scholar
• Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, Chumanevich A, Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila) 2010;3:549–59.
   PubMed Web of Science ®Google Scholar
• Warren CA, Paulhill KJ, Davidson LA, Lupton JR, Taddeo SS, Hong MY, Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis. J Nutr 2009;139:101–5.
   PubMed Web of Science ®Google Scholar
• Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005;288:G417–21.
   Web of Science ®Google Scholar
• Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80:S147–71.
   PubMed Web of Science ®Google Scholar
• Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003;16:658–72.
   PubMed Web of Science ®Google Scholar
• O'Sullivan GC, Kelly P, O'Halloran S, Collins C, Collins JK, Dunne C, Probiotics: an emerging therapy. Curr Pharm Des 2005;11:3–10.
   PubMed Web of Science ®Google Scholar
• Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 2006;8:486–98.
   PubMedGoogle Scholar
• Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007;115:1–11.
   PubMed Web of Science ®Google Scholar
• Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Hontecillas R. Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One 2012;7:e34676.
   PubMed Web of Science ®Google Scholar
• Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C. Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Am J Physiol Gastrointest Liver Physiol 2011;301:G1004–13.
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, Palladino G, Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 2011;6:e22978.
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim HM, Yang KM, Kim SA, Kim SK, An MJ, Bifidobacterium lactis inhibits NF-kappaB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice. Inflamm Bowel Dis 2010;16:1514–25.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005;140:417–26.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2009;184:1543–51.
   Google Scholar
• Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology 2009;137:914–23.
   PubMed Web of Science ®Google Scholar
• Park E, Jeon GI, Park JS, Paik HD. A probiotic strain of Bacillus polyfermenticus reduces DMH induced precancerous lesions in F344 male rat. Biol Pharm Bull 2007;30:569–74.
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72:5750–8.
   PubMed Web of Science ®Google Scholar
• Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45–56.
   PubMed Web of Science ®Google Scholar
• Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Gottl C, Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004;11:372–8.
   PubMedGoogle Scholar
• Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006;74:4075–82.
   PubMed Web of Science ®Google Scholar
• Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005;49:601–8.
   PubMed Web of Science ®Google Scholar
• Komiyama Y, Mitsuyama K, Masuda J, Yamasaki H, Takedatsu H, Andoh A, Prebiotic treatment in experimental colitis reduces the risk of colitic cancer. J Gastroenterol Hepatol 2011;26:1298–308.
   PubMed Web of Science ®Google Scholar
• Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001;86:291–300.
   PubMed Web of Science ®Google Scholar
• Bovee-Oudenhoven IM, ten Bruggencate SJ, Lettink-Wissink ML, van der Meer R. Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats. Gut 2003;52:1572–8.
   PubMed Web of Science ®Google Scholar
• Campbell JM, Fahey GC Jr, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr 1997;127:130–6.
   PubMed Web of Science ®Google Scholar
• Hsu CK, Liao JW, Chung YC, Hsieh CP, Chan YC. Xylooligosaccharides and fructooligosaccharides affect the intestinal microbiota and precancerous colonic lesion development in rats. J Nutr 2004;134:1523–8.
   PubMed Web of Science ®Google Scholar
• Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr 2003;133:21–7.
   PubMed Web of Science ®Google Scholar
• Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG, Siliart BS, Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2003;90:75–85.
   PubMed Web of Science ®Google Scholar
• Govers MJ, Gannon NJ, Dunshea FR, Gibson PR, Muir JG. Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs. Gut 1999;45:840–7.
   PubMed Web of Science ®Google Scholar
• Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991;26:747–50.
   PubMed Web of Science ®Google Scholar
• Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A, Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999;94:427–33.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Mitsuyama K, Saiki T, Agata K, Nakamura T, Iwanaga T. Preventive effects of germinated barley foodstuff on methotrexate-induced enteritis in rats. Int J Mol Med 1998;1:961–6.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Mitsuyama K, Andoh A. The therapeutic impact of manipulating microbiota in inflammatory bowel disease. Curr Pharm Des 2009;15:2074–86.
   PubMed Web of Science ®Google Scholar
• Koh SJ, Kim JS. Prebiotics: germinated barley foodstuff for the prevention of colitis-associated colon cancer? J Gastroenterol Hepatol 2011;26:1219–20.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Mitsuyama K, Andoh A, Iwanaga T. Modulation of intestinal environment by prebiotic germinated barley foodstuff prevents chemo-induced colonic carcinogenesis in rats. Oncol Rep 2008;20:793–801.
   PubMedGoogle Scholar
• Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S Jr, Mariadason JM, Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci USA 2006;103:7270–5.
   Google Scholar
• Lee SK, Il Kim T, Kim YK, Choi CH, Yang KM, Cellular differentiation-induced attenuation of LPS response in HT-29 cells is related to the down-regulation of TLR4 expression. Biochem Biophys Res Commun 2005;337:457–63.
   Google Scholar
• Fukuda M, Komiyama Y, Mitsuyama K, Andoh A, Aoyama T, Matsumoto Y, Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. J Clin Biochem Nutr 2011;49:57–61.
   PubMed Web of Science ®Google Scholar
• Kanneganti M, Mino-Kenudson M, Mizoguchi E. Animal models of colitis-associated carcinogenesis. J Biom Biotechnol 2011;2011:342637.
   PubMedGoogle Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805–20.
   PubMed Web of Science ®Google Scholar
• Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808–12.
   PubMed Web of Science ®Google Scholar
• Guarner F. Enteric flora in health and disease. Digestion 2006;73:5–12.
   PubMed Web of Science ®Google Scholar
• Perrin P, Pierre F, Patry Y, Champ M, Berreur M, Pradal G, Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 2001;48:53–61.
   PubMed Web of Science ®Google Scholar
• Erdman SE, Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 2010;38:76–87.
   Google Scholar
• Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009;29:2727–37.
   PubMed Web of Science ®Google Scholar
• Campbell FC, Maxwell RJ. Rationale for cancer prevention strategies in high-risk ulcerative colitis. Surgeon 2009;7:96–100.
   Google Scholar
• Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:(Suppl 2):1–5.
   Google Scholar